11.08

2.29% -0.26

After Hours: 11.08

Keros Therapeutics Inc (KROS)

Overview News Price History Option Chain Financials Why KROS Down? Discussions Forecast

Keros Therapeutics Inc stock is traded at $11.08, with a volume of 385.79K. It is down -2.29% in the last 24 hours and down -26.28% over the past month. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Previous Close:

$11.34

Open:

$11.16

24h Volume:

385.79K

Relative Volume:

0.89

Market Cap:

$218.47M

Revenue:

$244.06M

Net Income/Loss:

$87.01M

P/E Ratio:

6.0836

EPS:

1.8213

Net Cash Flow:

$105.95M

1W Performance:

-0.36%

1M Performance:

-26.28%

6M Performance:

-30.97%

1Y Performance:

+0.64%

1-Day Range:

$11.00

$11.60

1-Week Range:

$10.68

$11.60

52-Week Range:

$9.12

$22.55

Keros Therapeutics Inc Stock (KROS) Company Profile

Name

Keros Therapeutics Inc

Sector

Healthcare (1113)

Industry

Biotechnology (623)

Phone

617-314-6297

Address

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Employee

Twitter

Next Earnings Date

2026-02-27

Latest SEC Filings

KROS's Discussions on Twitter

Compare KROS vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KROS Keros Therapeutics Inc	11.08	223.60M	244.06M	87.01M	105.95M	1.8213
VRTX Vertex Pharmaceuticals Inc	453.74	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	756.73	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.16	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	692.83	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	147.60	31.97B	606.42M	-1.28B	-997.58M	-6.403

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Initiated	Wells Fargo	Overweight
Jun-10-25	Downgrade	BofA Securities	Buy → Neutral
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-16-24	Reiterated	Oppenheimer	Outperform
Dec-13-24	Reiterated	H.C. Wainwright	Buy
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy
Jun-25-24	Initiated	Oppenheimer	Outperform
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jul-31-23	Initiated	Wedbush	Outperform
Jul-26-23	Initiated	BofA Securities	Buy
Feb-14-23	Initiated	Cowen	Outperform
Oct-18-22	Initiated	Truist	Buy
Jul-26-22	Initiated	BTIG Research	Buy
Dec-08-20	Reiterated	H.C. Wainwright	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
May-04-20	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
May-04-20	Initiated	SVB Leerink	Outperform

View All

Keros Therapeutics Inc Stock (KROS) Latest News

Mar 25, 2026

Fed Meeting: What are Keros Therapeutics Incs technical support levels2026 Dividend Review & Fast Gain Swing Alerts - baoquankhu1.vn

Mar 25, 2026

KROS stock: What to know about Rinvatercept in DMD - MSN

Mar 25, 2026

Chart Watch: What is Keros Therapeutics Incs P E ratio telling us2026 Year in Review & Weekly Watchlist of Top Performers - baoquankhu1.vn

Mar 25, 2026

Institution Moves: Can Keros Therapeutics Inc weather a recessionM&A Rumor & Fast Gain Stock Tips - baoquankhu1.vn

Mar 25, 2026

Published on: 2026-03-25 15:00:50 - baoquankhu1.vn

Mar 25, 2026

Mar 24, 2026

KROS SEC FilingsKeros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 24, 2026

Mar 23, 2026

Pulmonary Arterial Hypertension Market: Expanding Revenue Landscape to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therapeutics - Barchart.com

Mar 23, 2026

Mar 22, 2026

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from S&P Biotechnology Select Industry Index - marketscreener.com

Mar 22, 2026

Precision Trading with Keros Therapeutics Inc. (KROS) Risk Zones - Stock Traders Daily

Mar 22, 2026

Mar 21, 2026

Quarterly Trades: Is now the right time to enter Keros Therapeutics Inc2026 Price Action Summary & Real-Time Volume Analysis - baoquankhu1.vn

Mar 21, 2026

Block Trades: Will RIVN benefit from current market trendsQuarterly Risk Review & High Conviction Buy Zone Alerts - baoquankhu1.vn

Mar 21, 2026

Mar 18, 2026

Can Keros Therapeutics Rinvatercept stand out in the DMD market? - MSN

Mar 18, 2026

Targets Report: Is Keros Therapeutics Inc likely to announce a buyback2026 EndofMonth & Expert Curated Trade Setup Alerts - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

KROS Pipeline Catalysts: DMD Phase II Progress and ALS Strategy for 2026 - Bitget

Mar 17, 2026

KROS Stock: What to Know About Rinvatercept in DMD - Yahoo Finance

Mar 17, 2026

Mar 16, 2026

KROS PE Ratio & Valuation, Is KROS Overvalued - Intellectia AI

Mar 16, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat

Mar 16, 2026

Mar 13, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of "Hold" from Analysts - MarketBeat

Mar 13, 2026

Mar 12, 2026

Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart

Mar 12, 2026

Myelofibrosis Market: Strong Pharma Growth Forecast Through - openPR.com

Mar 12, 2026

Mar 11, 2026

Keros Therapeutics (KROS) director submits initial Form 3 ownership - Stock Titan

Mar 11, 2026

Director adds Keros Therapeutics (NASDAQ: KROS) shares under 10b5-1 plan - Stock Titan

Mar 11, 2026

Technical Reactions to KROS Trends in Macro Strategies - Stock Traders Daily

Mar 11, 2026

Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), HeartFlow, Inc. (HTFL) - The Globe and Mail

Mar 11, 2026

Mar 10, 2026

Keros Therapeutics Partners with Healey & AMG Center for ALS to Launch Phase 2 Trial of Rinvatercept for ALS Treatment - Minichart

Mar 10, 2026

Mar 09, 2026

Keros Therapeutics Advances Rinvatercept in ALS Collaboration - TipRanks

Mar 09, 2026

Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference - Bitget

Mar 09, 2026

Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS - The Manila Times

Mar 09, 2026

Keros Therapeutics to Test Rinvatercept in Phase 2 ALS Trial with Mass General; Phase 1 Data Presented - TradingView

Mar 09, 2026

Keros (NASDAQ: KROS) moves rinvatercept toward Phase 2 in ALS, DMD - Stock Titan

Mar 09, 2026

Keros Therapeutics Presents Additional Clinical Data from - GlobeNewswire

Mar 09, 2026

Q1 EPS Estimate for Keros Therapeutics Decreased by Analyst - MarketBeat

Mar 09, 2026

Mar 07, 2026

Sell Signal: Does Keros Therapeutics Inc stock reflect fundamentals2025 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn

Mar 07, 2026

Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? - The Globe and Mail

Mar 07, 2026

Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen - MarketBeat

Mar 07, 2026

Is Keros Therapeutics Inc vulnerable to short sellers2025 Price Targets & Weekly Sector Rotation Insights - baoquankhu1.vn

Mar 07, 2026

Can Keros Therapeutics Inc be the next market leaderM&A Rumor & Daily Technical Stock Forecast Reports - baoquankhu1.vn

Mar 07, 2026

Is Keros Therapeutics Inc. stock a buy before product launchesPortfolio Value Summary & Growth Focused Stock Reports - Naître et grandir

Mar 07, 2026

Mar 06, 2026